96 Tests PN: B112512
45x Ab-conjugated beads (S4P8 - Human MIP-3β Ab-bead). PN: B112512A. One vial containing 100 µL of anti-Human MIP-3β conjugated to AimPlex Bead S4P8.
25x Biotin-detection Ab (Human MIP-3β Biotin-dAb). PN: B112512B. One vial containing 100 µL of biotinylated anti-Human MIP-3β.
Lyophilized Standard Mix-Human Group 6, Panel B, 12-Plex. PN: HG62013. One vial containing lyophilized recombinant Eotaxin-2, IGFBP-1, IGFBP-7, MCP-4, MDC, MIP-1δ, MIP-3α, MIP-3β, IL-6Rα, IL-1RII, Gp130, and TNFRII. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.
Application: Optimal antibody pair and antigen standard for assaying human CCL19/SCYA19/MIP-3β. Can be multiplexed with other analytes in Human Group 6. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
Storage: 2-8 C in the dark.
Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 10 pg/mL
LLOQ: < 20 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 6: Negligible
Sample volume: 15 µL/test
CCL19 (Chemokine C-C motif ligand 19) is also known as Small Inducible Cytokine Subfamily A (Cys-Cys), Member 19 (SYCA19) and macrophage inflammatory protein-3-beta MIP-3 beta, is a cytokine that may play a role in normal lymphocyte recirculation and homing, an important role in the trafficking of T cells in thymus, and in T cell and B cell migration to secondary lymphoid organs. CCL19 is expressed abundantly in thymus and lymph nodes, with moderate levels in trachea and colon and low levels in stomach, small intestine, lung, kidney and spleen. The gene for CCL19 is located on human chromosome 9. This chemokine elicits its effects on its target cells by binding to the chemokine receptor chemokine receptor CCR7. It attracts certain cells of the immune system, including dendritic cells and antigen-engaged B cells, CCR7+ central-memory T-Cells. Diseases associated with CCL19 include chronic inflammatory demyelinating polyradiculoneuropathy and polyradiculoneuropathy.
Weber C, Koenen RR (2006). "Fine-tuning leukocyte responses: towards a chemokine 'interactome'.". Trends Immunol. 27 (6): 268–73. doi:10.1016/j.it.2006.04.002. PMID 16678487.
Rossi DL, Vicari AP, Franz-Bacon K, et al. (1997). "Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3alpha and MIP-3beta". J. Immunol. 158 (3): 1033–6. PMID 9013939.
Nagira M, Imai T, Hieshima K, et al. (1997). "Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13". J. Biol. Chem. 272 (31): 19518–24. doi:10.1074/jbc.272.31.19518. PMID 9235955.
Kim CH, Pelus LM, White JR, et al. (1998). "CK beta-11/macrophage inflammatory protein-3 beta/EBI1-ligand chemokine is an efficacious chemoattractant for T and B cells". J. Immunol. 160 (5): 2418–24. PMID 9498785.